In close collaboration, Immuneed and CTC offer a unique preclinical risk assessment in conjunction with your clinical trial. Our unique approach provides early safety and effect data for a reliable risk assessment, optimized study design and a potential effect outcome of first-in-human (FIH) trials. Read more about the preclinical human model.
About the company: CTC Clinical Trial Consultants primarily acts as a full-service contract research organization (CRO). By providing their own clinic they also offer a more complete solution. Since 2011 they have conducted over 250 industry-sponsored clinical trials for start-up companies as well as for international pharmaceutical companies and CROs. Their track record includes, first-in-human, PET/MR, EPQT, drug-drug and food interaction, biosimilar, bioequivalence, and bioavailability studies, new drug delivery systems, medical device and Phase IIa studies.
By utilizing a unique 3D spheroid system composed of primary human hepatocytes and non-parenchymal cells, HepaPredict mimics in vivo liver tissue – making it possible to provide clients with hepatotoxicity predictions and pharmacokinetic assessments for their candidate drugs. HepaPredict’s system can also be adjusted to mimic liver diseases, thereby functioning as a validation tool for novel therapeutics.
ImmuMap offers customized flow cytometry assays and enzyme- or fluorescence-linked immunospot (ELISpot/fluorospot) for immune monitoring and consulting. ImmuMap has developed several platforms for high-throughput screening and profiling of antigen-specific T cells, including the Deep Profiling assay, providing multilayered characterization of specific T cell populations, and the dCODE™ platform, used for parallel identification and enumeration of 50–1031 different T cell specificities.